Mergers & Acquisitions ·
BeyondSpring completes sale of Chinese subsidiary to Biolin in exchange for clinical data rights and trial funding
BYSIBeyondSpring Inc.
BeyondSpring Inc. completed the closing of its Share Purchase and Collaboration Agreement with Biolin Investment Limited on September 30, 2026. The company sold its entire interest in BeyondSpring Ltd., which indirectly holds Dalian Wanchunbulin Pharmaceuticals (Bulin), to Biolin. No cash was paid; consideration consists of an exclusive license to clinical data from the China portion of the DUBLIN-4 Phase 3 trial for Plinabulin and Biolin's commitment to fund Bulin's conduct of that trial. The transaction includes a clawback provision requiring equity return if patient enrollment targets are not met. Pro forma financials reflect a preliminary estimated gain on disposition of $53,677 thousand, though this amount is excluded from continuing operations as it pertains to discontinued businesses. BeyondSpring Inc. operates in the biopharmaceutical industry, focusing on the development of oncology therapies.